A patient walked into my office last week wearing a Stelo on her arm, scrolling through fourteen days of glucose graphs on her phone. She had spent the previous two weeks discovering that oatmeal spiked her to 168 mg/dL, that her morning coffee with cream did nothing, that walking for ten minutes after dinner blunted her postprandial peak, and that her sleep quality on a low-glucose-variability day was visibly better than on a high-variability one. She wanted to know whether what she was seeing was clinically meaningful — or whether she had spent $99 to confirm what every nutrition textbook already said.
That is the right question, and most of the marketing around continuous glucose monitoring for non-diabetics does not answer it honestly. CGMs are one of the more interesting tools to enter the consumer wellness space in the last decade. They are also frequently misunderstood, oversold, and recommended to patients who do not need them. Whether one is worth your time and money depends on what you are actually trying to figure out.
What a CGM is actually measuring — and why that matters
The continuous glucose monitors available over the counter in 2026 — Dexcom Stelo, Abbott Lingo, Freestyle Libre Rio — measure interstitial glucose, not blood glucose. The sensor sits in subcutaneous fluid and reports a value every few minutes. There is a five-to-fifteen-minute lag between blood and interstitial glucose, which matters during rapid changes (like the immediate post-meal rise) but does not matter for trend analysis over a day or a week.
What a CGM gives you that a fasting fingerstick does not is the shape of your glucose curve. Fasting glucose is one number at one moment, after eight to twelve hours of no food. It tells you almost nothing about how your body handles a real meal in real life. The CGM shows you the postprandial rise, the peak, the time to return to baseline, the overnight pattern, and the day-to-day variability — collectively called your time-in-range and your glucose variability.
Two patients can have identical fasting glucose of 92 mg/dL and identical HbA1c of 5.4%. One spends most of the day between 80 and 110. The other spikes to 170 after every meal and drops to 65 in the late afternoon. Their conventional labs look the same. Their metabolic trajectory is not the same. The CGM is the tool that exposes that difference.
The mechanism question — why glucose variability matters at all
Glucose variability is not a vanity metric. The mechanistic literature over the last fifteen years has established that fluctuating glucose is metabolically more damaging than stable elevation at the same average. Repeated postprandial spikes drive endothelial dysfunction through oxidative stress and inflammatory cytokine release. They drive compensatory insulin secretion that, over time, contributes to the insulin resistance trajectory. They affect sleep architecture, hunger hormones, energy stability, and cognitive function in ways that an HbA1c does not capture.
Here is where my emergency and cardiac ICU background shapes how I think about this. The patients I admitted to the cath lab with new MIs in their fifties and sixties did not arrive with frank diabetes that someone had failed to treat. They arrived with twenty years of metabolic dysfunction that was missed because their fasting glucose stayed under 100 the whole time. Compensatory hyperinsulinemia maintains normal glucose for years before the system fails. By the time the HbA1c rises, the cardiovascular damage is already underway.
A CGM in the hands of a patient who is paying attention is one way to surface that dysfunction earlier — sometimes years earlier — than the standard primary care panel will catch it.
Who I think actually benefits from a CGM
When I evaluate someone in the medical weight loss program and the question of CGM comes up, my answer depends on the clinical picture. I am not interested in selling someone a wearable that will not change their plan.
Patients who genuinely benefit:
- Anyone with an elevated fasting insulin (above 8 mIU/L), elevated HOMA-IR, or triglyceride-to-HDL ratio above 2.0. These markers indicate metabolic dysfunction that has not yet shown up in glucose. A CGM gives the patient real-time feedback on which meals and behaviors are driving the dysfunction.
- Patients with PCOS, gestational diabetes history, or a strong family history of type 2 diabetes who currently look "normal" on standard labs. The early dysfunction shows up on the curve before it shows up on the average.
- Patients on a GLP-1 therapy who want to understand the mechanism of what the medication is doing for them. Watching your post-meal curve flatten on semaglutide is a powerful behavioral reinforcement that supports the longer-term work.
- Patients with unexplained energy crashes, post-meal sleepiness, or "hangry" episodes that resolve with eating. These are usually glucose excursions that a CGM will document precisely.
- Patients who have done years of conventional weight loss attempts without sustained success. Sometimes the answer is in the plate-by-plate data the CGM provides.
Patients who do not benefit much:
- Healthy lean patients with normal fasting insulin and no metabolic risk markers. The CGM data will be mostly reassuring and mostly unactionable.
- Patients prone to anxiety or disordered eating patterns. A CGM can fuel obsessive food monitoring in patients who do not need another reason to monitor. I steer these patients away from it.
- Patients who want a CGM as a substitute for the underlying clinical workup. The CGM is a supplementary tool. It is not a replacement for fasting insulin, full thyroid panel, sex hormone assessment, and the conversation about why weight loss has not worked.
What I look for when I review CGM data with a patient
Not sure where to start?
The Start Here pathway walks you through the most common entry points and helps you decide which consultation type is the right fit. Five minutes of self-assessment can save you a wrong-direction conversation.
When a patient brings two weeks of CGM data into a follow-up visit, I am looking at specific patterns that change the treatment plan.
Postprandial peak height. A peak above 140 mg/dL after a typical meal in someone with normal fasting glucose suggests early insulin resistance even when conventional labs are clean. Repeated peaks above 160 are a more urgent signal.
Time to return to baseline. Glucose that takes more than two hours to return to pre-meal level after a typical meal indicates impaired insulin response. Healthy metabolism returns to baseline within ninety minutes for most meals.
Overnight pattern. A flat overnight curve in the 80s is the goal. A creeping rise from 2 a.m. to 6 a.m. (the dawn phenomenon) indicates the early insulin resistance pattern. Overnight dips into the 60s with rebound spikes can signal reactive hypoglycemia from the previous evening's meal.
Variability metric. Coefficient of variation under 36% is the threshold for stable glycemic control. Above that, the day-to-day swing is producing the metabolic and symptomatic effects worth addressing.
Specific food patterns. What spikes you is partly individual. Two patients eating identical oatmeal can have completely different responses based on their individual metabolic context, what they ate the prior evening, their sleep quality, and their cortisol pattern that morning. The CGM tells the patient which foods are personally problematic, not which foods are theoretically problematic.
What I see most often in middle Georgia patients running CGMs
The patient population I see in Columbus and Warner Robins skews toward the demographic where insulin resistance is widespread and underdiagnosed. The military-affiliated population around Fort Benning is a partial exception — generally more active, generally more attentive to metabolic markers — but the broader middle Georgia population is solidly within the national pattern of high carbohydrate intake, high body composition, and hidden insulin resistance.
The CGM data I see in these patients is consistent with what the national epidemiology predicts. Sweet tea drives sustained glucose elevation that the patient had no idea was happening. Fast-food breakfasts produce four-hour-long postprandial curves. Beer with dinner does interesting things to the overnight pattern. The CGM is often the first piece of feedback that turns abstract advice ("eat better") into specific actionable change ("the chicken biscuit at this gas station spikes me to 180 every time").
How I integrate CGM data with the rest of the workup
The CGM is supplementary. The full evaluation in the medical weight loss program includes fasting insulin, HOMA-IR, full thyroid panel including reverse T3, sex hormone assessment (hormone optimization often matters more than people expect for metabolic outcomes), inflammatory markers, and a body composition assessment when indicated. CGM data alongside that lab picture produces a much more complete clinical view than either alone.
If a CGM run shows significant postprandial spikes and the labs show elevated fasting insulin, the plan is built around insulin sensitivity — which may include GLP-1 therapy, meal timing changes, structured resistance training, and, in many mid-life patients, hormone optimization. Nutritional counseling becomes much more concrete when the patient has personal data on what their own glucose does in response to specific meals, rather than generic dietary advice.
What I tell patients to do if they want to try one
If you want to run a fourteen-day CGM trial on your own before any clinical visit, that is reasonable. Wear it for the full sensor lifespan. Eat the way you normally eat for the first week — do not change anything. The point is to see your actual baseline pattern, not your aspirational one. In the second week, experiment: try a walk after dinner, swap your usual breakfast for a higher-protein version, see what happens to your overnight curve when you do not drink alcohol. Bring the data into your consultation.
If the data shows a clean curve with stable variability and reassuring peaks, you have learned something genuinely useful: your metabolism is in good shape and you do not need the wearable long-term. If the data shows the patterns I described above, that is the entry point to the actual clinical workup. Either outcome is worth the cost of a sensor.
The clinical next step
If your fourteen days of CGM data showed patterns that concerned you, or if you have been weighing whether your weight, energy, or metabolic trajectory needs a real evaluation, the next step is a complete metabolic workup — not another wearable. Take the weight loss assessment, bring the results and any CGM data into a consultation at the Columbus clinic or Warner Robins clinic, and we will run the full lab panel that turns interesting glucose graphs into a treatment plan that addresses the underlying mechanism. The CGM gave you the question. The workup gives you the answer.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider following appropriate evaluation. References to specific treatments, dosing, or protocols are informational.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
Ready to talk it through with a clinician?
Book online or call either Georgia location. Every visit starts with a consultation.